Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: Expression of FGF1 in CRC and paired normal tissues. (A) FGF1 mRNA levels in CRC and normal tissues in Skrzypczak’s datasets. (B) Comparison of FGF1 mRNA expression in CRC and normal tissues across 16 Oncomine datasets. (C) Representative IHC images showing in situ FGF1 expression in CRC and normal tissues (scale bar = 100μm). (D) IHC scores of FGF1 in CRC vs normal tissues. (E) OS of FGF1(+) and FGF1(-) in CRC patients in TCGA dataset searched via GEPIA platform. (F) OS of FGF1(+) and FGF1(-) in CRC patients. *** P < 0.001.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: Expressing, Comparison, In Situ

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: Statistics of FGF1 expression in 135 CRC tissues and adjacent normal tissue.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: Relationship between FGF1 and clinic-pathological factors in CRC patients.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques:

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: Results of univariate and multivariate analyses of underwent gastrectomy patients’ survival by Cox’s proportional hazard model.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: Effect of FGF1 on survival. (A) IHC images showing in situ FGF1 expression in CRC tissues (scale bar = 100μm). Negative (a), Weak (b), Moderate (c), Strong (d). (B) IHC scores of FGF1 in TNM stage I-II vs stage III-IV. (C) IHC scores of FGF1 in nLNM vs LNM. (D, E) OS of FGF1(+) and FGF1(-) CRC patients with TNM staging (D) I-II and (E) III-IV. nLNM, no lymph node metastasis; LNM, lymph node metastasis. ** P < 0.01.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: In Situ, Expressing

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: Subgroup analysis for the influence factor of survival duration of CRC patients according to FGF1 expression. * P < 0.05.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: The relationship between FGF1 and p-S6K1.Nomograms to predict survival of CRC patients. (A) Correlation analysis of FGF1 and S6K1 at gene level in CRC tissues from TCGA datasets by GEPIA platform. (B) Representative IHC images showing in situ p-S6K1 expression in CRC and normal tissues (scale bar = 100μm). (C) IHC scores of p-S6K1 in CRC vs normal tissues. (D–G) Correlation between FGF1 and p-S6K1 at protein level in (D) CRC tissue, (E) normal tissue, (F) TNM stage I-II tissue and (G) TNM stage III-IV tissue. (H) Stratification of 135 pairs of CRC and normal tissues into cluster 1 and cluster 2 according to FGF1 and p-S6K1 IHC scores. *** P < 0.001.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: In Situ, Expressing

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: FGF1 regulates CRC cell growth in an mTOR-S6K1 pathway dependent manner. (A) Immunoblot showing FGF1, p-mTOR, mTOR, p-S6K1 and S6K1, β-Actin protein levels in CRC cells transfected with FGF1-shRNA. (B) Immunoblot result of FGF1/β-Actin, p-mTOR/mTOR and p-S6K1/S6K1 were semi-quantified by ImageJ. Data are presented as mean ± SD. NC, negative control; KD, FGF1-shRNA. * P < 0.05, ** P < 0.01.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: Western Blot, Transfection, shRNA, Negative Control

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: FGF1 promotes proliferation and migration ability of CRC cells. (A, B) Colony formation capacity (A) and migration rates (B) of FGF1-KD CRC cells. CRC, colorectal cancer. (C) Wound healing assays were carried out at 24h after transfection in 6-well plates. The gap width was measured using Open Lab software. (D) The wound rate was calculated and displayed graphically according to the measured results by Open Lab software. NC, negative control; KD, FGF1-shRNA. Data are presented as mean ± SD (n=3). Ns, no significance, * P < 0.05.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: Migration, Transfection, Software, Negative Control, shRNA

Journal: Frontiers in Oncology

Article Title: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

doi: 10.3389/fonc.2021.706838

Figure Lengend Snippet: FGF1 induces CRC tumor growth in vivo . (A, B) Total body weight (A) and tumor volume (B) of the mice during the experiment. (C) Representative pictures of subcutaneous tumors harvested from NC and FGF1-KD group. (D) The weights of tumor masses. (E) Net body weight after subtracting the respective tumor weights. (F) Relative FGF1 mRNA levels in the tumors and the tumor weight correlation. (G) Stratification of mice into cluster 1 (blue) and cluster 2 (grey) according to tumor weight and FGF mRNA levels. (H) Percentage of NC and FGF1-KD mice in each cluster. Data are presented as mean ± SD (n=5). CRC, colorectal cancer. NC, negative control; KD, FGF1-shRNA. * P < 0.05.

Article Snippet: After blocking with 5% non-fat milk for 1h, the membranes were probed overnight with FGF1 (1:1000, BOSTER, China), p-mTOR (1:1000, Cell Signaling Technology, USA), mTOR (1:1000, Bioss, China), p-S6K1 (1:1000, Cell Signaling Technology, USA), and S6K1 (1:1000, Bioss, China) and β-Actin (1:5000, BOSTER, China) antibodies at 4°C with gentle shaking, followed by horseradish peroxidase-conjugated secondary antibodies.

Techniques: In Vivo, Negative Control, shRNA